About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Astex Pharma Announces It Will Halt Development of Lung Cancer Drug

by Kathy Jones on September 22, 2012 at 8:36 PM
Font : A-A+

 Astex Pharma Announces It Will Halt Development of Lung Cancer Drug

Astex Pharmaceuticals Inc has confirmed that it will be halting the development of experimental small-cell lung cancer drug, Amuvatinib. The reason is that the drug failed to achieve a high response rate on an ongoing study.

The main goal of the trial, known as ESCAPE, was to evaluate if the drug achieved a response rate of 10 percent. However Amuvatinib was able to achieve a rate of only 9.5 percent.

Advertisement

The company said in a statement that no new safety issues were identified during the trial and that it would license the drug to any other companies interested in developing it further.



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Liver Transplantation
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Lung Biopsy Lung Cancer Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Asbestosis Cancer Tattoos A Body Art Pneumoconiosis 

Most Popular on Medindia

The Essence of Yoga Hearing Loss Calculator How to Reduce School Bag Weight - Simple Tips Loram (2 mg) (Lorazepam) Pregnancy Confirmation Calculator Drug Side Effects Calculator A-Z Drug Brands in India Sanatogen Diaphragmatic Hernia Turmeric Powder - Health Benefits, Uses & Side Effects
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use